Prognostic Value of Routinely Measured Inflammatory Biomarkers in Older Cancer Patients: Pooled Analysis of Three Cohorts
| dc.rights.license | open | en_US |
| dc.contributor.author | OUBAYA, Nadia | |
| hal.structure.identifier | Actions for OnCogenesis understanding and Target Identification in ONcology [ACTION] | |
| dc.contributor.author | SOUBEYRAN, Pierre | |
| dc.contributor.author | REINALD, Nicoleta | |
| hal.structure.identifier | Actions for OnCogenesis understanding and Target Identification in ONcology [ACTION] | |
| dc.contributor.author | FONCK, Marianne | |
| dc.contributor.author | ALLAIN, Mylene | |
| dc.contributor.author | ZEBACHI, Sonia | |
| dc.contributor.author | HEITZ, Damien | |
| dc.contributor.author | LAURENT, Marie | |
| dc.contributor.author | DELATTRE, Cecile | |
| dc.contributor.author | CAILLET, Philippe | |
| dc.contributor.author | DAUBA, Jerome | |
| dc.contributor.author | BASTUJI-GARIN, Sylvie | |
| dc.contributor.author | ALBRAND, Gilles | |
| dc.contributor.author | BRINGUIER, Michael | |
| dc.contributor.author | RAINFRAY, Muriel | |
| dc.contributor.author | BRAIN, Etienne | |
| hal.structure.identifier | Actions for OnCogenesis understanding and Target Identification in ONcology [ACTION] | |
| dc.contributor.author | GRELLETY, Thomas | |
| dc.contributor.author | PAILLAUD, Elena | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MATHOULIN-PELISSIER, Simone | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BELLERA, Carine | |
| dc.contributor.author | CANOUI-POITRINE, Florence | |
| dc.date.accessioned | 2022-01-24T09:35:59Z | |
| dc.date.available | 2022-01-24T09:35:59Z | |
| dc.date.issued | 2021-12-07 | |
| dc.identifier.issn | 2072-6694 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/124599 | |
| dc.description.abstractEn | BACKGROUND: The prognostic assessment of older cancer patients is complicated by their heterogeneity. We aimed to assess the prognostic value of routine inflammatory biomarkers. METHODS: A pooled analysis of prospective multicenter cohorts of cancer patients aged >/=70 was performed. We measured CRP and albumin, and calculated Glasgow Prognostic Score (GPS) and CRP/albumin ratio. The GPS has three levels (0 = CRP </= 10 mg/L, albumin >/= 35 g/L, i.e., normal values; 1 = one abnormal value; 2 = two abnormal values). One-year mortality was assessed using Cox models. Discriminative power was assessed using Harrell's C index (C) and net reclassification improvement (NRI). RESULTS: Overall, 1800 patients were analyzed (mean age: 79 +/- 6; males: 62%; metastases: 38%). The GPS and CRP/albumin ratio were independently associated with mortality in patients not at risk of frailty (hazard ratio [95% confidence interval] = 4.48 [2.03-9.89] for GPS1, 11.64 [4.54-29.81] for GPS2, and 7.15 [3.22-15.90] for CRP/albumin ratio > 0.215) and in patients at risk of frailty (2.45 [1.79-3.34] for GPS1, 3.97 [2.93-5.37] for GPS2, and 2.81 [2.17-3.65] for CRP/albumin ratio > 0.215). The discriminative power of the baseline clinical model (C = 0.82 [0.80-0.83]) was increased by adding GPS (C = 0.84 [0.82-0.85]; NRI events (NRI+) = 10% [2-16]) and CRP/albumin ratio (C = 0.83 [0.82-0.85]; NRI+ = 14% [2-17]). CONCLUSIONS: Routine inflammatory biomarkers add prognostic value to clinical factors in older cancer patients. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject.en | Cancer | |
| dc.subject.en | Older patients | |
| dc.subject.en | Mortality | |
| dc.subject.en | Biomarkers | |
| dc.title.en | Prognostic Value of Routinely Measured Inflammatory Biomarkers in Older Cancer Patients: Pooled Analysis of Three Cohorts | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.3390/cancers13246154 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 34944774 | en_US |
| bordeaux.journal | Cancers | en_US |
| bordeaux.page | 6154 | en_US |
| bordeaux.volume | 13 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 24 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | EPICENE_BPH | |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03540655 | |
| hal.version | 1 | |
| hal.date.transferred | 2022-01-24T09:36:06Z | |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Cancers&rft.date=2021-12-07&rft.volume=13&rft.issue=24&rft.spage=6154&rft.epage=6154&rft.eissn=2072-6694&rft.issn=2072-6694&rft.au=OUBAYA,%20Nadia&SOUBEYRAN,%20Pierre&REINALD,%20Nicoleta&FONCK,%20Marianne&ALLAIN,%20Mylene&rft.genre=article |
